Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 652

1.

Evaluation of two rapid screening assays for detecting hepatitis C antibodies in resource-constrained settings.

Kosack CS, Nick S.

Trop Med Int Health. 2016 May;21(5):603-9. doi: 10.1111/tmi.12688. Epub 2016 Mar 29.

PMID:
26945920
2.

THE PERFORMANCE OF A RAPID TEST FOR ANTI-HCV SCREENING IN ORAL FLUIDS.

Comănescu C, Aramă V, Grancea C, Bleotu C, Rădulescu M, Tilişcan C, Botezatu A, Anton G, Ruţă S.

Roum Arch Microbiol Immunol. 2015 Jan-Jun;74(1-2):40-5.

PMID:
26727853
3.

Evaluating HBsAg rapid test performance for different biological samples from low and high infection rate settings & populations.

Cruz HM, Scalioni Lde P, de Paula VS, da Silva EF, do Ó KM, Milagres FA, Cruz MS, Bastos FI, Pollo-Flores P, Leal E, Motta-Castro AR, Pilotto JH, Lewis-Ximenez LL, Lampe E, Villar LM.

BMC Infect Dis. 2015 Nov 30;15:548. doi: 10.1186/s12879-015-1249-5.

4.

Prevalence of hepatitis B and C markers in a population of an urban university in Rio de Janeiro, Brazil: a cross-sectional study.

Pinto FP, Ferreira OC Jr, Olmedo DB, Precioso PM, Barquette FR, Castilho MC, Silva SG, Pôrto LC.

Ann Hepatol. 2015 Nov-Dec;14(6):815-25. doi: 10.5604/16652681.1171756.

PMID:
26436353
5.

Hepatitis C Virus Seroprevalence in Mongolian Women Assessed by a Novel Multiplex Antibody Detection Assay.

Dondog B, Schnitzler P, Michael KM, Clifford G, Franceschi S, Pawlita M, Waterboer T.

Cancer Epidemiol Biomarkers Prev. 2015 Sep;24(9):1360-5. doi: 10.1158/1055-9965.EPI-15-0351. Epub 2015 Jul 13.

PMID:
26169147
6.

Cost-effectiveness of strategies for testing current hepatitis C virus infection.

Chapko MK, Dufour DR, Hatia RI, Drobeniuc J, Ward JW, Teo CG.

Hepatology. 2015 Nov;62(5):1396-404. doi: 10.1002/hep.27966. Epub 2015 Aug 25.

PMID:
26126725
7.

Low cross-neutralization of hepatitis C correlates with liver disease in immunocompromized patients.

Maurin G, Halgand B, Bruscella P, Fresquet J, Duclos-Vallée JC, Roque-Afonso AM, Cosset FL, Samuel D, Lavillette D, Féray C.

AIDS. 2015 Jun 1;29(9):1025-33. doi: 10.1097/QAD.0000000000000651.

PMID:
26125137
8.

Utilization of Signal-to-Cutoff Ratio of Hepatitis C Virus Antibody Assay in Predicting HCV Viremia among Hemodialysis Patients.

Kao HH, Chen KS, Lin CL, Chang JJ, Lee CH.

Nephron. 2015;130(2):127-33. doi: 10.1159/000430988. Epub 2015 Jun 6.

PMID:
26065912
9.

Hepatitis C in Arkansas: updates on epidemiology, testing and treatment.

Beebe A, Quattlebaum T, Gicquelais RE, Zohoori N, Haselow DT, Smith NH, Patil N.

J Ark Med Soc. 2015 May;111(12):248-51.

PMID:
25966598
10.

HCV-specific lymphocyte responses in individuals with positive anti-HCV but negative HCV-RNA.

Sili U, Kaya A, Aydin S, Hondur N, Mert A, Tabak F, Ozaras R, Ozturk R.

J Clin Virol. 2015 Jun;67:73-7. doi: 10.1016/j.jcv.2015.04.014. Epub 2015 Apr 15.

PMID:
25959163
11.

Panel reactive antibodies in predicting hepatitis C virus treatment outcome in kidney transplant candidates.

Öcal S, Harmancı Ö, Korkmaz M, Ensaroğlu F, Çolak T, Selçuk H, Moray G, Haberal M.

Exp Clin Transplant. 2015 Apr;13 Suppl 1:193-6.

PMID:
25894153
12.

Comparison of HCV core antigen and anti-HCV with HCV RNA results.

Buket CA, Ayşe A, Selçuk K, Süleyman Ö, Emel SÇ.

Afr Health Sci. 2014 Dec;14(4):816-20. doi: 10.4314/ahs.v14i4.7.

13.

Relative efficacy of nucleic acid amplification testing and serologic screening in preventing hepatitis C virus transmission risk in seven international regions.

Bruhn R, Lelie N, Busch M, Kleinman S; International NAT Study Group.

Transfusion. 2015 Jun;55(6):1195-205. doi: 10.1111/trf.13024. Epub 2015 Feb 27.

PMID:
25727549
14.

Anti-hepatitis C virus seropositivity is not associated with metabolic syndrome irrespective of age, gender and fibrosis.

Cheng YL, Wang YC, Lan KH, Huo TI, Huang YH, Su CW, Lin HC, Lee FY, Wu JC, Lee SD.

Ann Hepatol. 2015 Mar-Apr;14(2):181-9.

15.

Diagnostic tests for hepatitis C: recent trends in electrochemical immunosensor and genosensor analysis.

Uliana CV, Riccardi CS, Yamanaka H.

World J Gastroenterol. 2014 Nov 14;20(42):15476-91. doi: 10.3748/wjg.v20.i42.15476. Review.

16.

Antibody screening tests variably overestimate the prevalence of hepatitis C virus infection among HIV-infected adults in Ghana.

King S, Adjei-Asante K, Appiah L, Adinku D, Beloukas A, Atkins M, Sarfo SF, Chadwick D, Phillips RO, Geretti AM.

J Viral Hepat. 2015 May;22(5):461-8. doi: 10.1111/jvh.12354. Epub 2014 Nov 14.

PMID:
25394987
17.

A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory.

Swadling L, Capone S, Antrobus RD, Brown A, Richardson R, Newell EW, Halliday J, Kelly C, Bowen D, Fergusson J, Kurioka A, Ammendola V, Del Sorbo M, Grazioli F, Esposito ML, Siani L, Traboni C, Hill A, Colloca S, Davis M, Nicosia A, Cortese R, Folgori A, Klenerman P, Barnes E.

Sci Transl Med. 2014 Nov 5;6(261):261ra153. doi: 10.1126/scitranslmed.3009185.

18.

Duplicate hepatitis C antibody testing in New York City, 2006-2010.

Tsai V, Bornschlegel K, McGibbon E, Arpadi S.

Public Health Rep. 2014 Nov-Dec;129(6):491-5.

19.

Seronegative occult hepatitis C virus infection: clinical implications.

Carreño V.

J Clin Virol. 2014 Nov;61(3):315-20. doi: 10.1016/j.jcv.2014.09.007. Epub 2014 Sep 28. Review.

PMID:
25304062
20.

Unrecognized chronic hepatitis C virus infection among baby boomers in the emergency department.

Galbraith JW, Franco RA, Donnelly JP, Rodgers JB, Morgan JM, Viles AF, Overton ET, Saag MS, Wang HE.

Hepatology. 2015 Mar;61(3):776-82. doi: 10.1002/hep.27410. Epub 2015 Jan 28.

PMID:
25179527
Items per page

Supplemental Content

Loading ...
Write to the Help Desk